André Schönichen, PhD, PMP, currently serves as Director of Diagnostics Development at Eli Lilly and Company, a role held since October 2025. Prior to this, André was Senior Director of Portfolio and Project Management at SiteOne Therapeutics, Inc. from April to October 2025, and Director of Development Project Management at Gilead Sciences from June 2020 to December 2024, where responsibilities included managing project timelines and facilitating team decision-making. André's experience also includes positions as Associate Director at Amgen, overseeing joint projects with diagnostic partners, and as Biomarker Research Project Manager at Thermo Fisher Scientific, directing biomarker discovery projects. André's academic background includes postdoctoral research at the University of California, San Francisco, and the Max Planck Institute, with a PhD in Biochemistry from TU Dortmund University.
This person is not in any teams
This person is not in any offices